Fulcrum Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $80,000 | $0 |
Gross Profit | 62,739 | -479 | ||
EBITDA | -19,060 | -22,694 | 55,809 | -29,355 |
EBIT | -19,429 | -23,063 | 52,492 | -29,834 |
Net Income | -16,568 | -21,696 | 55,409 | -26,870 |
Net Change In Cash | 0 | 0 | 80,000 | 0 |
Free Cash Flow | -16,992 | -19,091 | 58,899 | -25,312 |
Cash | 58,212 | 72,630 | 86,702 | 39,949 |
Basic Shares | 53,954 | 62,409 | 63,587 | 61,984 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $80,000 | $2,805 | $6,342 | $19,163 |
Gross Profit | 80,000 | 2,805 | 3,928 | 19,163 |
EBITDA | -18,241 | -108,492 | -109,720 | -78,539 |
EBIT | -19,834 | -110,664 | -112,134 | -81,054 |
Net Income | -9,725 | -97,335 | -105,621 | -78,332 |
Net Change In Cash | 80,000 | 2,805 | 6,342 | 19,163 |
Cost of Revenue | -314 | -21,640 | ||
Free Cash Flow | -2,496 | -91,473 | -99,013 | -80,191 |
Cash | 58,212 | 25,563 | 35,098 | 35,412 |
Basic Shares | 58,181 | 61,310 | 44,991 | 35,361 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.31 |
2024-09-30 | -$0.46 |
2024-06-30 | $0.87 |
2024-03-31 | -$0.43 |
